Remove Antibody Remove Gene Editing Remove Genomics Remove Reagent
article thumbnail

Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences

The Pharma Data

. “We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND,” said David Main , President and Chief Executive Officer of Notch.

article thumbnail

BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More

The Pharma Data

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform.

Drugs 52
article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases.

DNA 98